Media

Article published by Isabelle Mitchell, Top 100 Swiss Startup Magazine 2021 on 08.09.2021 20:32 Last year’s winner is this year’s runner-up: The CUTISS team wins silver at the TOP 100 Swiss Startup Award 2021 for developing unique personalized skin technology to treat skin defects. CUTISS’s denovoSkin™ is a safe, effective, and accessible therapy for children …

Article TOP 100 Swiss Startup Award 2021 Read More »

swissinfo.ch  “A Swiss company is offering hope to the more than 11 million people worldwide who suffer serious burns every year. The company is launching a revolutionary machine capable of generating skin that can be grafted in large quantities using a sample provided by the patient.” read more Photo: Copyright CSEM Newsroom LInk to article on …

swissinfo.ch: Swiss start-up develops world’s first ‘personalised skin’ machine Read More »

LE TEMPS, Wednesday, 25 June 2021 INNOVATION The Start-up Cutiss has taken an important step forward. With the CSEM, it has developed a machine allowingto automate the production of personalized skin grafts. Read the full article in French only. Photo: Copyright CSEM Newsroom LInk to Article

TeleTicino, Ticinonews 2e edizione 24.6.2021 Interview with Dr. Daniela Marino and reportage on CUTISS’s unveiling of the denovoCast, the world’s first automated machine to produce customized skin tissue grafts for adults and children with severe skin injuries, such as deep burns.  Watch the interview and reportage starting at minute 12:43.  Newsroom LInk to video

Article about our Chief Operations Officer, Mrs. Kathi Mujynya Ludunge, in the “Schlieremer” of November 2020

“It wasn’t always easy”

CUTISS’ management team consists of five people, including three women. One of them is 52-year-old Kathi Mujynya Ludunge. She has been Chief Operating Officer for a year. Until recently, CUTISS only had its research lab in Schlieren. The offices of the startup, which was founded in 2017, and the production facilities are now also located here. Mujynya Ludunge’s biggest challenge at the moment is therefore to establish and consolidate the operational structures in Schlieren, as well as to keep to the timelines and budget.

CUTISS is a life science company developing personalized skin grafting technologies for the treatment of a wide range of skin defects. European market approval for its most advanced product candidate, denovoSkin, is expected in 2023. Cutiss achieved 1st place in the “Top 100 Swiss Startup Award” competition this year. The company has thirty employees.

Mujynya Ludunge studied biology at the Ecole Supérieure de la Santé in Neuchâtel and subsequently completed a master’s degree in business administration at the University of Geneva. Later, she added a postgraduate diploma in Management of Biotech and Pharmaceuticals Venture at the EPF Lausanne. “I always wanted to have an overview and understand the big picture,” Mujynya Ludunge says of her current job. “At the same time, I want to positively develop organizations and share my energy and passion for science with others.” Mujynya Ludunge has led teams in Switzerland, the U.S. and Singapore over the past 18 years.

Her rise to leadership positions has “not always been easy,” Mujynya Ludunge explains. On the one hand, it was not common in the past for women to be represented at middle and senior management levels and also to be responsible for entire teams. On the other hand, she says, she is not only a woman, but also a “person of color” – her father is Congolese, her mother Swiss. “Fortunately, the world has become much more diverse in 2020,” Mujynya Ludunge says.

Mujynya Ludunge works between fifty and sixty hours a week. However, she is now getting better at not thinking about work on weekends, she says. She also has the good fortune of a large family, which keeps her busy in her private life. Mujynya Ludunge is married and the mother of five children. In her sparse free time, she reads a lot – “mainly between 11 p.m. and 1 a.m.”. She and her family also grow fruit and vegetables for their own use. With the garden’s harvest, she loves to cook for family and friends in the evenings and on weekends.

Article about our Chief Executive Officer, Dr. Daniela Marino, in SI Style of November 19, 2020

She preferred reading anatomy books to playing outside, even at the age of eight. Today, Daniela Marino heads the successful biotech startup Cutiss. What is her motivation? What is her superpower? And when was a day successful for her? We asked her 12 questions.

She grew up in Sicily as the daughter of a post office manager and an English teacher and had only one dream: to become a scientist. She studied biotechnology and came to Switzerland 15 years ago to do her PhD at ETH Zurich.

Daniela Marino aspired to an academic career, wanted to become a professor. But a research project changed everything. Today, the 39-year-old heads the life science company Cutiss, which produces personalized skin grafts. The innovative process involves growing new skin from the body’s own tissue. This reduces scarring in people with extensive skin injuries – and improves their quality of life. The University of Zurich spin-off has been showered with awards and funding for its groundbreaking idea. Around 30 employees recently moved into the brand-new headquarters, including a 500-square-meter laboratory, in Schlieren ZH.

Daniela Marino reveals how she went from scientist to founder, what she is particularly proud of and why she prefers to talk to herself in the interview format 12 Women, 12 Questions.

1) What’s the bravest thing you’ve ever done?

Becoming an entrepreneur. Business and management science had never interested me before, my world was science, my workplace was the lab. But when I saw the first test results of our invention, it was clear to me that we could really make a difference with it. Finding my role as CEO was a big challenge, not only professionally but also personally. But my motivation remains the same: I want to help people.

2) What are your principles as an entrepreneur?

The world deserves more entrepreneurs who are down-to-earth and honest. Sure, you need a vision, but to get to your goal you have to be very methodical. You always have to stay humble and take it one step at a time. It doesn’t do anyone any good to run headlong into a wall. Scientific thinking helps me to do just that. I’m very proud of my explorer brain. (laughs)

3) What people inspire you?

My idol from a very young age was the Italian Nobel Prize winner Rita Levi-Montalcini. In my childhood room, her poster hung next to Freddie Mercury’s. I think at one point my parents were quite worried because I wasn’t interested in boys like the other teen girls my age, preferring to read anatomy books and stories about knights and fairies all weekend long. My father believes that I inherited this fascination from his mother. She was never able to attend school, became a housewife. But in self-study she was engaged in astronomy and medicine.

4) How do you make difficult decisions?

I don’t wait too long, and I’m lucky in that I use my two brain hemispheres – the rational and the emotional – in a fairly balanced way. That is to say: First, I analyze the situation in detail, weighing the pros and cons of each piece of the puzzle. Then I let my instincts guide me. My head filters the options, my gut makes the decision.

5) When was a day successful for you?

When I’m not frustrated, my husband is not frustrated, our two children are not frustrated, and neither are my employees – in short, when everyone around me is happy. I realize that this can’t be the case every day, but it’s still my aspiration. And I believe that if the people around you see that you’re doing your best, they’ll be more forgiving of you if things don’t go smoothly.

6) What is your superpower?

My multitasking talent. The fact that I can be fully present to this conversation while thinking about what I need to get done this afternoon. That skill is almost essential for survival when you’re a mom and trying to build a company at the same time. Although I have to say that we don’t have a classic division of roles at our house: You rarely see me in the kitchen.

7) Where will your company be in five years?

We have grown very quickly and want to continue to be at the forefront of our field. In five years, we would like to be treating patients in Europe and be ready for the American market. Skin defects due to burns are a problem especially in emerging countries like India or Brazil. So our goal is clearly to be global. Perhaps our “Cutiss House” will become a “Cutiss Tower” in a few years. You have to think big to achieve big things.

8) How do you recharge your batteries?

With absolute peace and quiet. Of course, that’s not available in abundance in our networked world. That’s why I don’t impose clear offline times on myself. I don’t like strict rules, I prefer to find a healthy balance. It’s enough for me if I can take a relaxing bath for 20 minutes after work – no noise, no kids, no text messages. That’s where I can recharge.

9) Who do you call when you have a problem?

Before I call my husband or sister, I talk to myself – out loud and in English. This is not a joke. When I’m angry or have a problem, I talk to myself. I started doing that as a teenager and haven’t stopped until today. That’s why there are so many mirrors at home. (laughs)

10) What moment or person defined your career today?

It was in 2013, when I was invited to a business management course in the south of France as part of an EU funding program. I was able to take my husband and my then one-year-old daughter with me and thought to myself: great, we’ll take a week’s vacation on the beach and in between I’ll take some notes. But it turned out differently: we had a fantastic course instructor who was convinced that I was a natural. I will never forget that week. That was the moment I decided to become an entrepreneur.

11) When was the last time you doubted yourself?

Shortly after starting the company, I realized that I lacked the know-how to take the next step. I needed someone to add the necessary experience in business management to my drive and commitment. It was not easy to admit to myself that I was stuck. But today I’m glad I got the help I needed. It was the starting signal for our current team.

12) What are you most proud of?

Of what we are building as a company. But not in a business sense, but in a human sense. When I was able to hire my first employee, I cried with happiness. Our employees are becoming absolute experts in a field that is very trendy, modern and innovative. The future belongs to them – regardless of what happens to our company.

Even if she can now be found more often in boardrooms: In the lab, Daniela Marino feels completely in her element.

By Marlies Seifert on November 19, 2020

At the Credit Suisse REPLAY Panel three innovative Start-ups are presented. All of them are Spin-offs from the University of Zurich. Three female founders, together with
the Principal of the University of Zurich, Prof. Dr. Michael Schaepmann, talk about “Switzerland’s inventiveness”. Successful projects that could make the world a better place.

CUTISS’ Chief Clinical Officer Dr. Fabienne Hartmann-Fritsch talks about CUTISS’ bio-engineered skin which could become a hopeful treatment for burn victims. Further topics of the panel discussion are the financing, the hurdles and the role of women in leadership positions of young start-up companies.

> Introduction of Dr. Fabienne Hartmann-Fritsch starting at minute 07:22 – 13:35

> Panel discussion and Q&A as of minute 27:20

Interview by Startupdate with Chief Clinical Officer Dr. Fabienne Hartmann-Fritsch – November 12, 2020

“Flexibility is always needed”

We hear far more about men in leadership positions than women, yet female entrepreneurs are just as capable as their male counterparts. That’s why we talked to Fabienne Hartmann-Fritsch, co-founder of CUTISS AG. In the interview, she tells us who she would like to meet for lunch, what she would do with a few extra hours a day, and whether she ever doubted her idea.

Do you find it difficult to delegate tasks to others?

FABIENNE HARTMANN-FRITSCH: From academic research, I was used to delegating. Leading a team, however, was a change. For me personally, however, the responsibility to the patients and the authorities weighs much heavier.

How do you set priorities?

FH: I am a very organized person, I work in the classic way with lists, and I like to check off things that have been done. But flexibility is always needed, for example when a new study patient arrives.

Did you ever doubt your idea?

FH: No, the medical need is clearly there worldwide. But the most challenging part is definitely the cost-efficient manufacturing.

What’s the best professional advice you’ve ever received?

FH: I find Caspar Coppetti’s “Get the sh*t done” wonderfully simple and applicable to us as well.

What would you do if the day had 30 hours instead of 24?

FH: I would volunteer at Zurich Zoo, that would be a great balance for me. As an Antarctic enthusiast, I would prefer to work with the penguins.

FH: Which entrepreneur would you like to meet for lunch?

FH: Cristina Mittermeier, the founder of SeaLegacy, advocates for the world’s oceans with her organization. I would love to chat with her about her challenges in building and running her organization.

What has been the best moment of your career so far?

FH: Seeing our skin on a patient for the first time was a moving moment.

What advice would you give yourself at this same time last year?

FH: To set our 2020 annual plan for a pandemic… but I certainly wouldn’t have taken that advice.

Thank you very much for the interview!

Before becoming an entrepreneur, Winterthur native Fabienne Hartmann-Fritsch spent a long time in academic circles. In 2013, she completed her doctorate at the University of Zurich in the “Tissue Biology Research” unit, the research group in which the basic research for her skin replacement product “denovoSkin” was done. Since 2017, she is co-founder and Chief Clinical Officer at CUTISS AG.

CUTISS AG is a Swiss life science company that aims to provide patients with large and deep skin defects with the first automated personalized skin tissue therapy, denovoSkin™, a safe, effective and accessible therapy for children and adults.

Contributed photo: Frank Brüderli

Watch our CEO Daniela Marino talk on stage for TEDx Zurich Women about how much mothers and managers have in common.

Female managers with children have the great chance to train at home how to be better managers and to train at work how to be better mothers. Managers that are also mothers are tired, yes, but not unfocussed, they do not underperform. They do not need to be discouraged or discriminated against. Instead they need full support because being mothers and managers makes them beautiful creatures that have much more to give to society, future generations and the industry. As a scientist, a young entrepreneur and a mother, Daniela’s mission is to foster healthy and sustainable growth of both her family and her business – she believes with creativity, sacrifice, and passion, marvelous things can be achieved. Despite wanting to be a researcher since she was 7 years old, her curiosity, determination and risk tolerance made her leave her scientific career to build a life science start-up, CUTISS AG, with the vision to bring personalized skin tissue therapy to help patients with skin defects. This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at https://www.ted.com/tedx

Article in the Swiss Economy Magazine ‘Finanz und Wirtschaft’ (Saturday, 21 March 2020)

Daniela Marino likes her espresso macchiato hot and strong. The company she runs, Cutiss, is also in a hot phase. Due to time constraints, the CEO, who is originally from Italy, usually drinks her coffee at the office, which is located near the University of Zurich. That’s where Cutiss’ human skin production technology was originally developed.

Worldwide, at least fifty million people suffer from large-scale skin injuries every year. The standard treatment today is to take skin from a healthy part of the body and place it on the injured area so that it grows back and closes the wound. Thus, an additional injury is created, which can also leave its scars. This is where the Cutiss procedure is supposed to provide a step forward. Only a small skin biopsy needs to be taken. It is taken apart in the laboratory, the cells obtained from it are reproduced and then combined with a collagen hydrogel to form a new type of skin substitute. Cutiss is thus in a similar category to manufacturers of cell therapies, in which body cells are also removed, manipulated and reintroduced.

In a Phase I study, denovoSkin was successfully tested for safety in ten patients at the Children’s Hospital of the University of Zurich. Swissmedic, the EU’s Medicines Agency (EMA) and its US counterpart, the FDA, have granted denovoSkin orphan drug status. This would mean that the product would enjoy longer market protection and could also be approved more quickly.

First, however, Phase II studies are needed in which the laboratory-produced skin is tested not only for its safety but also for its efficacy. These studies are already underway in Switzerland and the Netherlands. They are expensive and are expected to last until 2022, so Marino is looking for additional funding worth CHF 30 million, she says, adding that some existing shareholders are willing to participate in the capital increase. “But we are also looking for new shareholders, and we especially need a long-term anchor investor who would contribute several million and support our vision,” Marino explains. The 38-year-old studied biotechnology in Milan and completed her doctorate at the ETH. As part of a post-doctorate at the University of Zurich, she then worked with the Tissue Biology Research team on the cultivation and production of personalized skin. After initial studies on humans turned out positive, it made sense in 2017 to found a start-up for further development.

The work in the lab is just the beginning. “The breakthrough for this technology will only come when we succeed in automating the manufacturing process,” Marino is convinced. Her company is thus entering the world of mechanical engineering. To this end, she has brought competent partners on board in the form of the engineering company Zühlke and the Centre Suisse d’Electronique et de Microtechnique.
Innosuisse is supporting the development with just under CHF 1 million. Cutiss has already raised a total of CHF 21 million, including CHF 3 million from the European Union and CHF 5 million from Wyss Zurich, the incubator of the University of Zurich and the ETH founded from a donation by Hansjörg Wyss. Cutiss thus moves between biotech, surgery and process automation. “That doesn’t make it any easier for us to find investors,” Marino admits. But she is confident that she will soon have the necessary funds together. This is despite the fact that the current situation surrounding the coronavirus is also causing investors to be cautious.
If the results of the Phase II trials are good, Cutiss could already submit a marketing authorization application for denovoSkin. The green light from regulators could follow about a year later. Primarily, burn victims would benefit. In addition, reconstructive surgery after other accidents or, for example, reconstructive surgery to remove a large mole would also be important. According to Cutiss’ estimates, this alone would represent a market (Europe and the USA) of CHF 2 billion.

In contrast to existing products, Cutiss’ skin is thicker, consists of the patient’s own cells and contains both a dermal and an epidermal skin layer, allowing it to attach better and wounds to heal better. This also leads to less scarring. This is a factor that should not be underestimated, because many patients suffer psychologically for the rest of their lives from disfigurement caused by their injuries and subsequent treatments.

The greatest challenge for Marino is the upcoming growth spurt of her company, which currently employs twenty people. The company’s own research and development center and a production facility are being built in the Biotechnopark in Schlieren. “We still need at least ten new employees,” says Marino. She has long since finished her espresso macchiato. She looks at her watch and says a friendly goodbye.

Text: Rupen Boyadjian